主页 > 医学文档 >
【drug-news】研究表明关节炎药物致癌风险被夸大
Cancer risk from arthritis drugs overstated-study
Tue Nov 7, 2006 4:42pm ET
WASHINGTON (Reuters) - Two biotech drugs used to treat rheumatoid arthritis -- Abbott Laboratories Inc.'s Humira and Johnson & Johnson's Remicade -- may raise the risk of cancer and infections but not as much as was feared, researchers said on Tuesday.
A series of letters published in the Journal of the American Medical Association show that several teams have taken a fresh look at the safety of the two drugs and find that they may double the risk of cancer and infections.
Most of the researchers, and the U.S. Food and Drug Administration, agree that patients need to know about the risks but say the benefits mean the drugs should stay on the market.
In May, a study published in the Journal showed that Humira, known generically as adalimumab, and Remicade, known generically as infliximab, tripled the risk of cancer and some infectious diseases such as tuberculosis in patients who used them.
This information had already been included in labels put on the drugs after a directive from the FDA six months earlier.
Dr. Eric Matteson and colleagues at the Mayo Clinic in Rochester, New York, who did the study published in May re-analyzed the data and added more data from other studies they had not considered before.
"We re-did the analysis completely," Matteson said in a telephone interview. The new analysis showed the cancer risk was 2.4 times greater among patients who used the drugs, and the risk of infectious disease was 1.8 times greater.
"The magnitude is still higher in treated groups than in untreated groups," Matteson said. Continued...
This would be expected. Rheumatoid arthritis is an autoimmune disease, in which the immune system mistakenly attacks the joints. The drugs target TNF-alpha, one of the immune system's signaling compounds.
"Anything that modifies our immune systems does have the potential for causing cancers," Matteson said.
His team is looking at a third drug in the same class, Amgen's Enbrel, known generically as etanercept. "We don't have data yet," Matteson said. "We do think that there's a concern, which is why we are looking."
So far, studies have shown no link between Enbrel and cancer or infectious diseases.
Rheumatoid arthritis affects about 2 million Americans and represents a rapidly growing market that could reach more than $11 billion by 2014, according to market research company Research and Markets.
Drugs approved to treat it also often work against skin conditions such as psoriasis, ulcerative colitis and similar autoimmune conditions. Cancer risk from arthritis drugs overstated-study
Tue Nov 7, 2006 4:42pm ET
研究表明关节炎药物致癌风险被夸大
WASHINGTON (Reuters) - Two biotech drugs used to treat rheumatoid arthritis -- Abbott Laboratories Inc.'s Humira and Johnson & Johnson's Remicade -- may raise the risk of cancer and infections but not as much as was feared, researchers said on Tuesday.
华盛顿（路透通讯社）----研究者于星期二表明抗类风湿性关节炎的两生物技术药致癌和诱发感染的可能性没有像人们想象的那样。
A series of letters published in the Journal of the American Medical Association show that several teams have taken a fresh look at the safety of the two drugs and find that they may double the risk of cancer and infections.
发表在美国医学联合杂志上的一系列文章表明，几个研究组织对两个药物的安全性作了重新研究并发现它们可能使癌症和感染的发生机率增加2倍。
Most of the researchers, and the U.S. Food and Drug Administration, agree that patients need to know about the risks but say the benefits mean the drugs should stay on the market.
大多数研究者和美国的食品药品管理机构认为患者有必要知道他的危险性，但由于这两种药仍有它的作用所以它们仍会在市场上流通。
In May, a study published in the Journal showed that Humira, known generically as adalimumab, and Remicade, known generically as infliximab, tripled the risk of cancer and some infectious diseases such as tuberculosis in patients who used them.
五月份刊登于杂志上的一项研究表明，Humira（类属于阿达木单抗）和Remicade（类属于英夫利昔单抗）能使使用他们的患者得癌症和感染（如结核）的几率增加3倍。
This information had already been included in labels put on the drugs after a directive from the FDA six months earlier.
六个月前，美国FDA已经要求将此信息标在药物的标签上。
Dr. Eric Matteson and colleagues at the Mayo Clinic in Rochester, New York, who did the study published in May re-analyzed the data and added more data from other studies they had not considered before.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-26 17:11
医学,生命科学网